Affinity Asset Advisors’s Orchestra BioMed OBIO Stock Holding History

Affinity Asset Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Sell	33,400 -369,150	-92%	-$1.51M	0.01%	110
2026 Q1	$1.71M	Sell	402,550 -170,254	-30%	-$725K	0.09%	95
2025 Q4	$2.38M	Sell	572,804 -154,468	-21%	-$623K	0.14%	79
2025 Q3	$1.8M	Buy	+727,272	New	+$2.01M	0.16%	77
2022 Q2	–	Sell	-300,000	Closed	-$2.97M	–	61
2022 Q1	$2.97M	Hold	300,000	–	–	0.48%	31
2021 Q4	$3M	Hold	300,000	–	–	1.09%	34
2021 Q3	$2.97M	Hold	300,000	–	–	0.75%	33
2021 Q2	$3.06M	Buy	300,000 +75,000	+33%	+$776K	1.1%	21
2021 Q1	$2.52M	Buy	225,000 +25,000	+13%	+$304K	0.86%	35
2020 Q4	$2.56M	Buy	+200,000	New	+$2.28M	1.36%	20

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Affinity Asset Advisors's OBIO Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Orchestra BioMed (OBIO) stake by 92% in Q2 2026, selling an estimated $1.51M and leaving 33,400 shares worth $144K. The position accounts for 0.01% of the portfolio, ranked #110.

Affinity Asset Advisors first reported a position in OBIO in Q4 2020 and has held it in 10 quarters since. The position peaked at $3.06M in Q2 2021. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Affinity Asset Advisors held 33,400 shares of Orchestra BioMed worth $144K as of Q2 2026.
Affinity Asset Advisors sold 369,150 Orchestra BioMed shares in Q2 2026, an estimated $1.51M.
Orchestra BioMed made up 0.01% of Affinity Asset Advisors's portfolio in Q2 2026, its #110 holding.
Affinity Asset Advisors first reported a position in Orchestra BioMed in Q4 2020 and has held it in 10 quarters since.
Affinity Asset Advisors's Orchestra BioMed position peaked at $3.06M in Q2 2021.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.